<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Cephalosporins: Four Generations of Beta-Lactam Antibiotics</title>
  <meta charset="utf-8">
  
  <link href="urology.css" rel="stylesheet">

<meta name="keywords" content="cephalosporins, " >
<meta name="description" content="Cephalosporins are an important group of &beta;-lactame antibiotics, which are grouped in four generations with different antibiotic spectrums, from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <h5 id="logo">urology-textbook.com</h5>
       <p>Dr. med. Dirk Manski</p>
    </a>  
</header>
<main>
<nav id="navigation">
<ul>
<li><a href="https://www.urology-textbook.com/index.html">Start</a></li>
<li><a href="https://www.urology-textbook.com/anatomy.html">Anatomy</a></li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>



 
</nav>
<article>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; Cephalosporins</p><!-- Main content -->

<h1>Cephalosporins: Four Generations of Beta-Lactam Antibiotics</h1>

<h2>Four Generations of Cephalosporins</h2>

<img src="https://images.urology-textbook.com/cephalosporines.jpg" alt="structural formula of cephalosporins" title="Cephalosporins">
<br>
<p>Cephalosporins are &beta;-lactam antibiotics, which are grouped into four generations according to their antibiotic spectrum of activity (<a href="#SimonStille1997">Simon and Stille, 1997</a>). The first generation has mainly gram-positive activity. The second and third generation has more gram-negative activity with decreased activity against gram-positive bacteria. The fourth generation of cephalosporins has a broad spectrum of activity. The following list provides an overview of the generations of cephalosporins with significant substances:</p>
<ul title="generations of cephalosporins">
<li>First generation: cefazolin, cefalexin, cefadroxil</li>
<li>Second generation: cefamandole, cefoxitin, cefaclor, cefuroxime, loracarbef, cefotetan</li>
<li>Third generation: cefotaxime, cefpodoxime, ceftizoxime, ceftriaxone, ceftazidime, cefoperazone
</li>
<li>Fourth generation: cefepime, cefozopran, cefpirome, cefquinome
</li>
</ul>

<br>
<a name="cefazolin"></a>
<h2>Cefazolin</h2><h3>Antibiotic Spectrum of Cefazolin</h3> 

<p>Cefazolin is a first-generation cephalosporin. Cefazolin has a comparable antibiotic spectrum to penicillin. In addition, cefazolin has activity against gram-negative bacteria (E. coli, Klebsiella) and staphylococci.</p>

<h3>Urologic Indications for Cefazolin</h3> 

<ul title="urologic indications for cefazolin" type="disc">
<li>Staphylococci infections</li>
    <li><a href="https://www.urology-textbook.com/surgical-site-infections.html">Wound infections</a></li>
<li>Perioperative antibiotic prophylaxis</li>
<li>Cefazolin can replace penicillin for a penicillin allergy. Patients with penicillin allergy have a low risk of cross-allergy (10%), even lower with second and third-generation cephalosporins.</li>
</ul><h3>Pharmacokinetics of Cefazolin</h3> 

<p>Cefazolin is only for parenteral administration available. The elimination half-life is 1.5 h, with 90% renal elimination.</p>

<h3>Side Effects of Cefazolin</h3>

<ul title="side effects of cefazolin">
<li>Allergy: 1&ndash;4%. Usually, there is a small risk for cross-allergy to a penicillin (10%)
</li>
<li>Allergic neutropenia</li>
<li>Positive direct Coombs test, very rarely hemolytic anemia.</li>
<li>Inhibiting the effect of anticoagulants or antiplatelet agents</li>
</ul>

<h3>Contraindications of Cefazolin</h3> 

<p>Cephalosporin allergy. </p>

<h3>Dosage of Cefazolin</h3> 

<p>In adults, the dosage of cefazolin is 1 g 1-1-1 i.v. Children receive a daily dose of 60&nbsp;mg/kg body weight, divided into three doses. Dose reduction is necessary for renal insufficiency. </p>

<a name="cefuroxime"></a>
<h2>Second Generation of Cephalosporins</h2>

<p>Cefuroxime, cefotiam, and cefaclor are essential substances of the second generation of Cephalosporins. </p>

<h3>Antibiotic Spectrum of Second-Generation Cephalosporins</h3>
<p>Good activity against streptococci, gonococci, meningococci, Haemophilus, and staphylococci. High &beta;-lactamase resistance. No efficacy against Pseudomonas, enterococci, mycoplasma, and chlamydia. </p>

<h3>Urologic Indications of Cefuroxime:</h3> 

<ul title="urologic indications for cefuroxime" type="disc">
<li><a href="https://www.urology-textbook.com/urinary-tract-infection.html">Urinary tract infection</a></li>
<li>Treatment of <a href="https://www.urology-textbook.com/gonorrhea.html">gonorrhea</a></li>
<li>Staphylococci infections</li>
    <li><a href="https://www.urology-textbook.com/surgical-site-infections.html">Surgical site infections</a></li>
<li>Perioperative antibiotic prophylaxis</li>
<li>Cefuroxime can replace penicillin for a penicillin allergy. </li>
</ul>

<h3>Pharmacokinetics of Cefuroxime and Cefotiam</h3> 

<p>Cefuroxime can be applied per os or intravenously. The elimination half-life is 1 hour with 70&ndash;90% renal elimination.</p><h3>Side Effects of Cefuroxime</h3>

<ul title="side effects of cefuroxim">
<li>Allergy: 1&ndash;4%. There is a minimal risk for cross-allergy to penicillin.</li>
<li>Allergic neutropenia</li>
<li>Positive direct Coombs test, very rarely hemolytic anemia.</li>
<li>Inhibiting the effect of anticoagulants or antiplatelet agents</li>
</ul>

<h3>Contraindications of Cefuroxime</h3> 

<p>Cephalosporin allergy.</p>

<h3>Dosage of Cefuroxime and Cefotiam</h3> 

<p>In urinary tract infections: cefuroxime 250&ndash;500&nbsp;mg 1-1-1 p.o., 750&nbsp;mg 1-1-1 i.v. or 1 g cefotiam 1-1-1 i.v., depending on the severity of infection <a href="#Ovalle2000">Ovalle et al. 2000</a>. Children receive 25&nbsp;mg/kg i.v. 1-1-1. Double the dosage in severe infections. Dose reduction is necessary for renal insufficiency.</p>

<a name="ceftriaxone"></a>
<h2>Third Generation of Cephalosporins</h2>

<p>Important substances of third-generation cephalosporins are cefotaxime and ceftriaxone (cefotaxime-group).</p>

<h3>Antibacterial Spectrum of cefotaxime and ceftriaxone</h3> 

<p>Cefotaxime and Ceftriaxone show good activity against streptococci, gonococci, meningococci, Haemophilus, and staphylococci. High &beta;-lactamase resistance. Weak activity against Pseudomonas. No activity against enterococci, mycoplasma, chlamydia, and multidrug-resistant Staphylococcus aureus.</p>

<h3>Urologic Indications for Third-Generation Cephalosporins</h3> 

<ul title="urologic indications for third generation cephalosporins">
<li>Severe urinary tract infections: consider a combination with gentamicin to include enterococci.</li>
<li>Severe postoperative infections like peritonitis: consider a combination with gentamicin to include enterococci. </li>
<li>Treatment of gonorrhea: with a single intramuscular injection of ceftriaxone.</li>
</ul><br>



<h3>Pharmacokinetics of Cefotaxime and Ceftriaxone</h3> 

<p>Only parenteral administration of cefotaxime and ceftriaxone is possible. The elimination half-life is one hour for cefotaxime and 7&ndash;8&nbsp;h for ceftriaxone. 50% renal elimination.
</p>

<h3>Side Effects of Cefotaxime and Ceftriaxone</h3>
 
<ul title="side effects of cefotaxime and ceftriaxone">
<li>Allergy: 1&ndash;4%. There is a minimal risk for cross-allergy to penicillin.
</li>
<li>Allergic neutropenia</li>
<li>Positive direct Coombs test, very rarely hemolytic anemia.</li>
<li>Inhibition of the efficacy of anticoagulants or antiplatelet agents</li>
<li>Alcohol intolerance possible</li>
</ul>

<h3>Contraindications</h3> 

<p>Cephalosporin allergy.</p>

<h3>Dosage of Cefotaxime and Ceftriaxone</h3> 

<p><i>Treatment of severe infection:</i> the daily dosage of cefotaxime in adults amounts to 3&ndash;6 g (children 50&ndash;100&nbsp;mg/kg), depending on the severity of the infection, and is divided into three doses. The daily dosage for ceftriaxone is 2&ndash;4 g in two doses. Dose reduction is necessary with a renal insufficiency below a <a href="https://www.urology-textbook.com/kidney-glomerular-filtration-rate.html">glomerular filtration rate</a> of 5 ml/min.</p><p><i>Single shot treatment of gonorrhea:</i> 250&nbsp;mg ceftriaxone i.m. [see Chapter <a href="https://www.urology-textbook.com/gonorrhea.html">gonorrhea</a>].
</p>

<h2>Oral Cephalosporins</h2>
<a name="ceftibuten"></a>
<h3>Ceftibuten</h3>

<p>
Ceftibuten is an oral cephalosporin with high activity against Enterobacteriaceae. It is suitable for treating severe or complicated urinary tract infections in children 
<a href="#Ho2001">Ho et al., 2001</a> <a href="#Vilaichone2001">Vilaichone et al., 2001</a>.
</p>

<h4>Pharmacokinetics of Ceftibuten:</h4> <p>The elimination half-life is 2.5 h with 70% renal elimination.</p>

<h4>Dosage of Ceftibuten:</h4> <p>400&nbsp;mg 1-0-0 in adults, 9&nbsp;mg/kg body weight 1-0-0 in children.</p>

<h3>Cefixime</h3>
<a name="cefixime"></a>
<p>Cefixime is a derivative of cefotaxime, which can be given orally. Cefixime is suitable for treating urinary tract infections in children <a href="#Gok2001">Gok et al., 2001</a> <a href="#Ho2001">Ho et al., 2001</a>.</p>

<h4>Pharmacokinetics of Cefixime:</h4> <p>The elimination half-life is 2.5 h, only 20% renal elimination, high biliary excretion.</p>

<h4>Dosage of Cefixime:</h4> <p>Adults 200&nbsp;mg 1-0-1 or 400&nbsp;mg 1-0-0 p.o., children 4&nbsp;mg/kg body weight 1-0-1 or 8&nbsp;mg/kg 1-0-0. </p>

<a name="cefpodoxime"></a>
<h3>Cefpodoxime</h3>

<p>
Cefpodoxime is a derivative of ceftizoxime. Cefpodoxime is suitable for the oral treatment of urinary tract infections.</p>

<h4>Pharmacokinetics of cefpodoxime:</h4> 
<p>The elimination half-life is 2.5 h with 30&ndash;40% renal elimination.<h4>Dosage of cefpodoxime:</h4> <p>Adults 200&nbsp;mg 1-0-1 and children 4&nbsp;mg/kg body weight 1-0-1.</p>

<br>
<br>

<table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/surgical-management.html">Surgical management</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<br>
<hr><h3>References</h3>


<p><a NAME="Gok2001">
    Gok u.a. 2001 G<SMALL>OK</SMALL>, F.&nbsp;; D<SMALL>UZOVA</SMALL>, A.&nbsp;;
      B<SMALL>ASKIN</SMALL>, E.&nbsp;; O<SMALL>ZEN</SMALL>, S.&nbsp;; B<SMALL>ESBAS</SMALL>, N.&nbsp;;
      B<SMALL>AKKALOGLU</SMALL>, A.:
    </a>
     Comparative study of cefixime alone versus intramuscular ceftizoxime
      followed by cefixime in the treatment of urinary tract infections in
      children.
    <br> In: <I>J Chemother</I>
    <br> 13 (2001), Nr.&nbsp;3, S.&nbsp;277&ndash;80</p>


<p><a NAME="Ho2001">
    Ho u.a. 2001 H<SMALL>O</SMALL>, M.&nbsp;W.&nbsp;; W<SMALL>ANG</SMALL>, F.&nbsp;D.&nbsp;;
      F<SMALL>UNG</SMALL>, C.&nbsp;P.&nbsp;; L<SMALL>IU</SMALL>, C.&nbsp;Y.:
    </a>
     Comparative study of ceftibuten and cefixime in the treatment of
      complicated urinary tract infections.
    <br> In: <I>J Microbiol Immunol Infect</I>
    <br> 34 (2001), Nr.&nbsp;3, S.&nbsp;185&ndash;9</p>


<p><a NAME="Ovalle2000">
    Ovalle u.a. 2000 O<SMALL>VALLE</SMALL>, A.&nbsp;; M<SMALL>ARTINEZ</SMALL>,
      M.&nbsp;A.&nbsp;; W<SMALL>OLFF</SMALL>, M.&nbsp;; C<SMALL>ONA</SMALL>, E.&nbsp;; V<SMALL>ALDERRAMA</SMALL>, O.&nbsp;;
      V<SMALL>ILLABLANCA</SMALL>, E.&nbsp;; L<SMALL>OBOS</SMALL>, L.:
    </a>
     [Prospective, randomized, comparative study of the efficacy, safety
      and cost of cefuroxime versus cephradine in <a href="https://www.urology-textbook.com/acute-pyelonephritis.html">acute pyelonephritis</a> during pregnancy].
    <br> In: <I>Rev Med Chil</I>
    <br> 128 (2000), Nr.&nbsp;7, S.&nbsp;749&ndash;57</p>


<p><a NAME="SimonStille1997">
    Simon und Stille 1997 S<SMALL>IMON</SMALL>, C.&nbsp;; S<SMALL>TILLE</SMALL>, W.:
    </a>
     <I>Antibiotika-Therapie in Klinik und Praxis</I>.
    <br> 9. Auflage.
    <br> Stuttgart New York&nbsp;: Schattauer, 1997</p>


<p><a NAME="Vilaichone2001">
    Vilaichone u.a. 2001 V<SMALL>ILAICHONE</SMALL>, A.&nbsp;; W<SMALL>ATANA</SMALL>,
      D.&nbsp;; C<SMALL>HAIWATANARAT</SMALL>, T.:
    </a>
     Oral ceftibuten switch therapy for acute pyelonephritis in children.
    <br> In: <I>J Med Assoc Thai</I>
    <br> 84 Suppl 1 (2001), S.&nbsp;S61&ndash;7</p>
<br>
<br>
<p><img src="https://images.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/cephalosporine.html">Cephalosporine</a></p>
<br>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
	
	<img src="https://vg08.met.vgwort.de/na/15fcbea3018d4a7dad12c35297d4de58" width="1" height="1" alt="">

</footer>
</body>
</html>
